| Title |
|
Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells. |
|
|
| Publication Date |
|
| Author(s) |
|
| Type of document |
|
| DOI |
|
10.1007/s00262-009-0672-0 |
|
|
| Abstract |
|
"Cancer stem cells" that resist conventional treatments may be a cause of therapeutic failure in melanoma. We report a subpopulation of clonogenic melanoma cells that are characterized by high prominin-1/CD133 expression in melanoma and melanoma cell lines. These cells have enhanced clonogenicity and self-renewal in vitro, and serve as a limited in vitro model for melanoma stem cells. In some cases clonogenic CD133(+) melanoma cells show increased expression of some cancer/testis (CT) antigens. The expression of NY-ESO-1 in an HLA-A2 expressing cell line allowed CD133(+) clonogenic melanoma cells to be targeted for killing in vitro by NY-ESO-1-specific CD8(+) T-lymphocytes. Our in vitro findings raise the hypothesis that if melanoma stem cells express CT antigens in vivo that immune targeting of these antigens may be a viable clinical strategy for the adjuvant treatment of melanoma. |
|
|
| Link |
|
| Citation |
|
Cancer Immunology, Immunotherapy : Cii 2009; 58(10): 1635-46 |
|
|
| Jornal Title |
|
Cancer immunology, immunotherapy : CII |
|
|
